Study drug for certain B-cell cancers in Chinese participants
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This early-stage study tests a new medicine (BGB-16673) that targets B-cell cancer cells in people with specific lymphoma or related blood cancers. It aims to see how well the drug can control the cancer and what side effects it causes, especially in Chinese participants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign consent paperwork before any study procedures
- Your overall health/activity level is ECOG 0 to 2 (you’re not severely limited)
- You have enough heart/liver/kidney/pancreas (organ function) for the study tests
- You have one of the listed diagnoses (for Phase 2: mantle cell lymphoma or CLL/SLL)
- You are able to use highly effective birth control during treatment and for at least 90 days after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial studies the safest dose and then effectiveness of BGB-16673 in people with specific B-cell malignancies. It may help by targeting cancer cells in these blood cancers, especially after other treatments like BTK inhibitors.
This Phase 1 trial studies LP-168 taken by mouth in people whose B-cell cancers have come back or did not respond to treatment. The study aims to find how the drug works, the right dose, and what side effects to expect.
This early (Phase 1) study tests SGR-1505, an experimental treatment, in people with certain mature B-cell cancers. It’s mainly designed to see how the drug works in the body and to check safety, and it may offer an option if standard treatments aren’t enough.
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
This trial tests two targeted drugs, zanubrutinib and sonrotoclax, together for people with certain types of B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. It focuses on enrolling patients from racial and ethnic groups that are often underrepresented in research.
This early-stage trial tests a new drug called GSK5926371 in adults whose B-cell lymphoma (a blood cancer) has come back or stopped responding to previous treatments. The study aims to find out if this drug is safe and whether it can help shrink the cancer.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.